MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.19
+0.55
+2.66%
After Hours: 21.19 0 0.00% 17:22 08/12 EDT
OPEN
20.69
PREV CLOSE
20.64
HIGH
21.33
LOW
20.45
VOLUME
427.74K
TURNOVER
--
52 WEEK HIGH
21.76
52 WEEK LOW
6.35
MARKET CAP
1.19B
P/E (TTM)
-13.4463
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KURA stock price target is 24.75 with a high estimate of 28.00 and a low estimate of 22.00.

EPS

KURA News

More
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 12h ago
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 1d ago
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 3d ago
Kura Oncology, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 4d ago
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings: Kura Oncology (NASDAQ:KURA): $300M. Alphatec Holdings (NASDAQ:ATEC): $200M. Dynava
seekingalpha · 5d ago
Kura Oncology EPS beats by $0.02
Kura Oncology (NASDAQ:KURA): Q2 GAAP EPS of -$0.40 beats by $0.02. Cash, cash equivalents and short-term investments of $338.9M. Press Release
seekingalpha · 5d ago
Kura Oncology Reports Second Quarter 2020 Financial Results
GlobeNewswire · 6d ago
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
GlobeNewswire · 08/04 12:30

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+1.61%

Hot Stocks

Symbol
Price
%Change

About KURA

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
More

Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.